North America Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Castrate-Resistant Prostate Cancer Market
Market Report Description
The North America Castrate-resistant Prostate Cancer Market would witness market growth of 7.5% CAGR during the forecast period (2020-2026). The cases of castrate-resistant prostate cancer are increasing across the world due to the high prevalence of prostate cancer that grows into castrate-resistant prostate cancer in the later years of diagnosis. There are millions of men who get diagnosed with the disease every year in the US. However, Metastatic castrate-resistant Prostate Cancer has been increasing at a significant rate. Better prognosis is associated with the increasing trend of initial diagnosis of the condition. These rising cases of castrate-resistance prostate cancer patients around the globe have driven the market growth, which further increases its demand.
Prostate cancer is a type of cancer that develops into male reproductive systems. Generally, prostate cancer is slow-growing and stable but it may spread from the prostate (gland) to different part of the body like bone and lymph node. In the beginning, prostate cancer does not show any kind of symptom but in some serious cases, it causes pain during urination and can even cause a problem during sexual intercourse. Castration-resistant prostate cancer referred to prostate cancer that reached other body parts and resists medical or surgical treatment.
The high-risk factor for castration-resistant prostate cancer involves the geriatric population, genetic predisposition, medication exposure, unhygienic diet, and many sexual partners. Detection of castration-resistant prostate cancer is done by prostate imaging, tumor marker, biopsy, and staging test. The main thing about castration-resistant prostate cancer is that it’s resistance to medical and surgical treatment. Although, there are various available options in the market such as hormone therapy, antiangiogenic treatment, immune modulation, and bone targeted therapies.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
- Hormonal Therapy
- Rest of North America
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free